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Abstract
Background: Transarterial chemoembolization (TACE) is the most common treatment for patients with
unresectable hepatocellular carcinoma (HCC). Post-embolization syndrome (PES) is a common post-
TACE complication. The goal of this study was to evaluate PES as an early predictor of the long-term
outcome.
Methods: A retrospective cohort study of HCC patients treated with TACE at a tertiary referral centre
was performed (2008–2014). Patients were categorized on the basis of PES, defined as fever with or
without abdominal pain within 14 days of TACE. The primary outcome was overall survival (OS). Multi-
variate Cox regression was done to examine the association between PES and OS.
Results: Among 144 patients, 52 (36.1%) experienced PES. The median follow-up for the cohort was
11.4 months. The median and 3-year OS rates were 16 months and 18% in the PES group versus
25 months and 41% in the non-PES group (log rank, P = 0.027). After multivariate analysis, patients
with PES had a significantly increased risk of death [hazard ratio 2.0 (95%CI 1.2–3.3), P = 0.011].
Conclusions: PES is a common complication after TACE and is associated with a two-fold increased
risk of death. Future studies should incorporate PES as a relevant early predictor of OS and examine
the biological basis of this association.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
malignancy worldwide with over 700 000 new cases diagnosed
annually and is the second leading cause of cancer-related
death.1,2 It is the fastest growing cause of cancer-related mor-
tality, and has a poor prognosis with 5-year overall survival
(OS) rates of less than 12%.3 Liver transplantation and liver
resection are the only potentially curative treatments, but only
a small proportion of patients are candidates for these thera-
pies.4,5 A number of locoregional liver-directed therapies are
currently available for patients not amenable to curative
treatment, with transarterial chemoembolization (TACE)
among the most commonly used. TACE is indicated as a pri-
mary treatment (palliative), in combination with other treat-
ments, or as a bridge to surgery – more commonly while
waiting for liver transplantation.6,7
As a primary treatment, TACE has been associated with an
improved OS when compared with best supportive care in
several randomized trials, with reported 3-year OS rates of
26–47%, as compared with as low as 3% for untreated
patients.8–10 These findings have been confirmed by at least
three recent meta-analyses,11–13 and support recommendations
by the American Association for the Study of Liver Diseases
(AASLD) and other international guidelines to use TACE as
the treatment of choice for patients with advanced, unre-
sectable HCC.6,14 Based on this, it is estimated that TACE will
target at least 20% of the HCC population, and indeed, a
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population-level study from Japan revealed that TACE was the
most commonly used therapy, treating over 36% of patients
presenting with HCC.14,15 Notwithstanding the improved sur-
vival observed with TACE, a number of prognostic factors such
as vascular invasion and advanced liver disease have been
found to carry a significantly worse prognosis,16 and TACE
provides only a minimal survival benefit in these settings for
which alternative and more effective therapies are evolving.17
Likewise, recent studies have emphasized the role of inflamma-
tory serum markers as prognostic factors after TACE. However,
no clinical data have been identified to correlate these with a
worse prognosis.18–20 Although TACE has been shown to be
safe with low rates of severe complications,5,21,22 post-em-
bolization syndrome (PES) – a post-inflammatory clinical syn-
drome defined by fever and right upper quadrant abdominal
pain with or without nausea and vomiting – is a common
complication,23–27 and there are currently no available data
evaluating the impact of PES on the long-term outcome.
Based on this, using a contemporary cohort of HCC patients,
we sought to characterize the incidence of PES after TACE and its
association with long-term outcomes. The primary goal of the
present study was to examine the impact of PES on OS in patients
with advanced, unresectable HCC, who received TACE as the
primary treatment strategy. Our hypothesis was that patients
experiencing PES after TACE are at an increased risk of death,
and that in the setting of other validated risk factors, PES can be
used as an early predictor of worse survival for this population.
Patients and methods
Study design
This is a retrospective cohort study of HCC patients treated
with TACE at the Michael E. DeBakey VA Medical Center
(MEDVAMC) in Houston, TX, USA. The Baylor College of
Medicine institutional review board and the MEDVAMC
Research & Development Committee approved the research
protocol and waived the requirement to obtain informed con-
sent and HIPAA authorization.
Study setting
The study was conducted at the MEDVAMC in Houston, TX,
which is one of 10 VA medical centres within the South Cen-
tral VA Veterans Integrated Service Network (VISN 16).
VISN16 provides care for close to 2 million veterans across
eight different states. MEDVAMC serves as a tertiary regional
and national referral centre for the evaluation and treatment of
patients with HCC in the VA system. All patients with HCC
referred to the MEDVAMC are evaluated in a multidisciplinary
setting during a weekly HCC-specific tumour board, which is
staffed by all disciplines involved in the care of HCC and
represents the treatment modalities available locally [i.e. trans-
plant, liver resection, ablation, interventional radiology-based
liver-directed therapies (including TACE), radiation and
systemic therapy].
Study population and data collection
All patients with a confirmed diagnosis of HCC diagnosed by
imaging and/or biopsy who were treated with TACE by the
MEDVAMC interventional radiology service between 1 Decem-
ber 2008 and 30 June 2014 were eligible for study inclusion.
Patients were included if they met the diagnostic criteria for
HCC and were treated with TACE as the primary treatment
strategy. Patients were excluded if they received any treatment
in addition to TACE such as chemotherapy, liver resection,
liver transplantation and/or liver ablation procedures, if they
had TACE for any diagnosis other than HCC and/or if they
had metastatic disease at the time of first TACE (Fig. 1).
Data collection was performed using direct chart review by a
trained abstractor with pre-defined algorithms and definitions,
and included demographic information, clinical characteristics,
measures of liver function, tumour characteristics and Barce-
lona Clinic Liver Cancer (BCLC) staging. Details regarding the
TACE procedure included the embolization technique (selec-
tive versus non-selective), the chemotherapy regimen used
(single agent versus multiple agents), the type of TACE [con-
ventional versus drug-eluting beads (DEB-TACE)] and the
number of TACE procedures performed for each patient. A
collection of post-TACE information included the occurrence
of complications and severity according to the Dindo–Clavien
classification.28 PES was recorded, and defined as a fever with/
without right upper quadrant abdominal pain without evi-
dence of sepsis, occurring within 14 days of the first TACE
procedure.24,26 As our goal was to include PES as a measure of
Total unique patients at MEDVAMC
who received successful TACE
procedure from 12/2008-06/14
(n = 225)
Patients (n = 214)
Patients (n = 211)
FINAL (n = 144)
Excluded patients (n = 11)
TACE procedure for diagnosis other than HCC
Excluded patients (n = 3)
Diagnosis of metastatic disease
Excluded patients (n = 67)
Received TACE as part of bridging/
combination treatment
Figure 1 Flow diagram of study design and inclusion/exclusion
criteria. HCC, hepatocellular carcinoma; MEDVAMC, Michael E.
DeBakey VA Medical Center in Houston, TX; PES, post-
embolization syndrome (defined in Methods); TACE, transarterial
chemoembolization
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the inflammatory process, we chose to focus on the clinical
hallmark of PES – fever – and did not include measures of
cytolysis such as changes in transaminase levels. Additionally,
previous studies have described a good correlation between
cytolysis and fever after TACE.29 Patients were followed with
cross-sectional imaging (MRI and/or CT) and laboratory tests
1 month after TACE and every 3 to 4 months thereafter. The
vital status was assessed for all patients, and the date of death
was verified when applicable, using the VA electronic medical
record and the social security death index.
Statistical analysis
Patients were categorized based on PES, and descriptive
statistics were used to compare baseline data and procedure
characteristics. Categorical variables were compared using the
two-sided chi-square test, and continuous variables were com-
pared using the Student’s t-test, Mann–Whitney U-test and
Kruskal–Wallis test, as appropriate. The primary outcome of
interest was OS, which was measured from the date of the
TACE procedure to the date of death of any cause. Patients
were censored if alive at the date of last follow-up. OS was
estimated using the Kaplan–Meier method and differences in
survival functions were compared using the log-rank test.
Multivariable Cox regression analysis was performed to assess
the association of PES with OS while adjusting for important
covariates. The selection of variables for inclusion in the multi-
variate model was clinically and statistically driven (P < 0.1 on
univariate analysis for the primary outcome). PES was also
examined as a secondary outcome, and univariate and multi-
variate logistic regression analyses were done to identify predic-
tors of PES using the same approach. Hazard ratios (HR) or
odds ratios (OR) and their 95% confidence intervals (CI)
were calculated accordingly. A P-value < 0.05 was considered
statistically significant for all analyses. STATA version 12
(STATACORP, College Station, TX, USA) was used to perform
all statistical analyses in the study.
Results
Baseline clinical characteristics
A total of 144 HCC patients met the criteria and were included
in the study (Fig. 1). Baseline characteristics are summarized
in Table 1. Notably, 142 (98.6%) were male, with the majority
having a significant burden of comorbidities (Charlson’s index
≥ 3 = 79.9%), cirrhosis (95.8%) and associated portal hyper-
tension (69.4%). Likewise, the majority of patients had multi-
focal disease (> 1 tumour = 68.1%) and 17 (11.8%) had
macroscopic vascular invasion (MVI) at presentation. Accord-
ing to BCLC staging, the majority of patients had intermediate
or more advanced disease (43.8%), with 16.7% of patients hav-
ing unstaged disease.
Table 1 Baseline clinical, tumour and TACE-procedure character-
istics, and post-TACE complications for all the study cohort (N =
144)
Characteristic Frequency (%)
Demographic Characteristics
Mean Age, years (SD) 62.0 (6.7)
Age
<65 years 101 (70.1)
≥65 years 43 (29.9)
Gender
Male 142 (98.6)
Female 2 (1.4)
Race
White 85 (59.0)
Non-white 59 (41.0)
Ethnicity
Hispanic 13 (9.0)
Other 131 (91.0)
Clinical Characteristics
Mean BMI, kg/m2 (SD) 28.0 (5.1)
Obesity
BMI <30 95 (66.0)
BMI ≥30 49 (34.0)
ECOG performance status
0–1 106 (73.6)
2–4 4 (2.8)
Unknown 34 (23.6)
Charlson’s Comorbidity index
0–2 29 (20.1)
≥3 115 (79.9)
HCC Aetiology
HCV 45 (31.3)
Alcohol 11 (7.6)
HCV + Alcohol 69 (47.9)
HBV + Alcohol 5 (3.5)
HBV + HCV + Alcohol 2 (1.4)
Other/Unknown 12 (8.3)
Liver Cirrhosis 138 (95.8)
Portal Hypertension 100 (69.4)
Liver Function
Child-Pugh Class
A 80 (55.6)
B 51 (35.4)
C 13 (9.0)
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TACE characteristics and complications post-TACE
The first TACE procedure was successful in 99.3% of the cases
with only one patient requiring a second procedure to accomplish
chemoembolization. In the majority of the cases, a selective
approach targeting the vessel feeding the tumour was used (91%),
with only 13 cases requiring a non-selective strategy. Conven-
tional TACE was used in close to one-fourth of all patients, but
the majority of the procedures during the whole study period used
DEB-TACE (76.4%). Importantly, although the median number
of TACE procedures was one (IQR 1–5), 41.7% of patients had
more than one TACE procedure performed (Table 1).
In all, 70 patients (48.6%) had one or more complications
within 30 days after the initial TACE procedure, and only 6
(4.2%) had severe complications (Dindo class ≥ 3) including
one death. The most common complication was PES, occur-
ring in a total of 52 patients (36.1%). Details of the specific
complications are listed in Table 1.
Overall survival and post-embolization syndrome
The median follow-up for the whole cohort was 11.4 months
(IQR 0.6–49.9). Median and 1-, 3- and 5-year OS rates were
20 months, and 71%, 32% and 0%, respectively. On univariate
analysis, when comparing patients with and without PES, sur-
vival was significantly better for the latter group with a median
OS of 25 months versus 16 months, and 1- and 3-year OS
rates significantly higher (77% versus 56%, and 41% versus
18%, respectively, P = 0.027) (Fig. 2a). After adjusting for
other important variables, PES was associated with an
increased risk of death as compared with those without PES
[HR 2.0 (95% CI 1.2–3.3); P = 0.011] (Table 2).
Other independent predictors of overall survival
Table 2 displays results from the multivariate Cox regression
model. In addition to PES, the presence of MVI [HR 4.5
(2.4–8.6); P < 0.001] and advanced liver disease [Child-Pugh
Table 1 Continued
Characteristic Frequency (%)
Median MELD Score (Range) 10 (6–23)
Tumour Characteristics
Median AFP, ng/ml (Range) 17.8 (1.5–303 000)
Tumour Type
Primary 134 (93.1)
Recurrent 10 (6.9)
Number of tumours
Solitary 46 (31.9)
Multiple 98 (68.1)
Median largest tumour size, cm (Range) 3.3 (1–18.5)
Distribution
Unilobar 84 (58.3)
Bilobar 60 (41.7)
Macrovascular invasion 17 (11.8)
BCLC Staging
Early 57 (39.6)
Intermediate 42 (29.2)
Advanced 13 (9.0)
Terminal 8 (5.6)
Unknown 24 (16.7)
Procedure Characteristics
Procedure success – first attempt 143 (99.3)
Technique
Selective 131 (91.0)
Non-Selective 13 (9.0)
TACE type
Traditional 34 (23.6)
Beads 110 (76.4)
Chemotherapy type
Single Agent 108 (75.0)
Multiple Agent 36 (25.0)
Number of TACE procedure >1 60 (41.7)
Median number of TACE procedures (Range) 1 (1–5)
Post-TACE complications
Any Complication 70 (48.6%)
Severe Complication (Dindo ≥3)a 6 (4.2%)
GI bleeding 4 (2.7%)
Severe hyperbilirubinemia (total bilirubin ≥7.0) 2 (1.4%)
Respiratory failure 1 (0.7%)
Death 1 (0.7%)
Mild Complication 64 (44.4%)
PESb 52 (36.1%)
Nausea/vomiting 13 (9.0%)
Mild hyperbilirubinemia (total bilirubin <7.0) 7 (4.9%)
Table 1 Continued
Characteristic Frequency (%)
Ascites 5 (3.5%)
Hepatic encephalopathy 3 (2.1%)
Otherc 17 (11.8%)
aSevere complications classified as Dindo ≥ 3 includes patients who
had one or more of the following that occurred within 30 days of the
first TACE procedure: GI bleeding, severe hyperbilirubenemia (total
bilirubin ≥7.0), and/or death.
bPost-embolization syndrome, defined as a fever with or without right
upper quadrant abdominal pain within 14 days of the first TACE proce-
dure.
cOther includes: acute kidney injury, urinary retention, haematoma,
post-procedure anaemia, pleural effusion, thrombocytopenia, and/or
pneumonia.
AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; DEB-
TACE, beads; BMI, body mass index; GI, gastrointestinal; HCC, hepa-
tocellular carcinoma; HCV, hepatitis C virus; PES, post-embolization
syndrome; TACE, transarterial chemoembolization.
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class B HR 1.9 (1.0–3.4); P = 0.040, and Child-Pugh class C
HR 6.3 (2.7–14.5); P < 0.001] were both associated with an
increased risk of death. In contrast, having multiple TACE pro-
cedures, was associated with a protective effect (HR 0.4 [0.3–0.8];
P = 0.004), when compared with those having only one
TACE during the course of the study period. Additional
Kaplan–Meier curves for each of these predictors are displayed
in Fig. 2b–d.
Predictors of post-embolization syndrome
After univariate analysis and using the pre-determined selec-
tion criteria, four variables were included in the multivariate
logistic regression model. Bilobar versus unilobar disease [OR
2.07 (1.01–4.24); P 0.048] and the use of DEB-TACE, as
compared with conventional TACE, [OR 0.44 (0.19–0.98); P
0.045] were identified as independent predictors of PES, while
tumour size [OR 0.57 (0.23–1.41); P 0.223] and a non-selective
approach [OR 2.21 (0.67–7.22); P 0.191], were not associated
with this outcome. Other tumour-related variables such as pre-
TACE AFP levels had no correlation with the occurrence of
PES.
Discussion
TACE is the most commonly used therapy for patients with
HCC and has been shown to provide a survival benefit in
those with unresectable disease not amenable to curative treat-
ment.6,14 Although a relatively safe procedure, TACE is often
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Figure 2 Overall survival for HCC patients (N = 144) after a TACE procedure, by (a) the presence of post-embolization syndrome, (b) the
presence of macrovascular invasion, (c) liver function using Child–Pugh classification and (d) the number of TACE procedures performed.
HCC, hepatocellular carcinoma; MEDVAMC, Michael E. DeBakey VA Medical Center in Houston, TX; MVI, macrovascular invasion; PES,
post-embolization syndrome (defined in Methods); TACE, transarterial chemoembolization
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associated with post-embolization syndrome, a clinical syn-
drome mediated by an inflammatory response associated with
the embolization itself and/or chemotherapeutic agent deliv-
ered.23–27 Although, a number of studies have shown an associ-
ation between inflammatory markers after TACE and worse
survival,18–20 the role of PES as a prognostic factor in patients
with HCC has not been studied. The goals of our study were
to examine the incidence of PES in a contemporary cohort of
HCC patients treated with TACE and to evaluate its role as an
early predictor of worse OS. Using a strict definition, we found
that PES was the most common complication after TACE,
occurring in over one-third of patients, and after adjusting for
important variables, it was associated with a two-fold increased
risk of death. Further, we were able to identify specific
tumour- and procedure-related characteristics that were associ-
ated with the increased risk of PES, including bilobar disease
and the use of conventional TACE (as compared with DEB-
TACE). These results are significant because, in the context of
other well-established prognostic factors, PES can be used to
identify a population at an increased risk of death early during
the treatment plan. Similarly, understanding that patients are
at increased risk of PES provides important information when
considering competing treatment alternatives in patients not
amenable to surgical treatment.
There are a number of noteworthy points derived from these
findings. First, the incidence of PES after TACE varies widely
in the literature ranging from 15% up to 90%.23,25,26 This
variation is likely related to measurement bias derived from
differences in the definitions used and a lack of appropriate
follow-up and/or capture of events. We found a PES incidence
of 36% using a strict definition based solely on clinical parame-
ters. Although subject to this definition, our results corroborate
the high incidence of PES in this population of patients, and
this pre-defined criteria allows for future comparisons focused
on validating these results. Second, we found that PES after
TACE was associated with a worse survival and a two-fold
increased risk of death, after adjusting for important con-
founders. Few studies have explored this association. Jun and
colleagues recently published a similar analysis in which no
association was found between PES and 20-months overall sur-
vival.30 Although these findings are important, they need to be
interpreted within the context of marked differences between
such a study and ours; specifically, their study included
patients from South Korea treated with TACE using lipiodol
infusion (100%) – which in turn was associated with higher
incidence of PES – whereas in the present study patients were
predominantly treated with drug-eluting beads (76%), a more
contemporary and accepted strategy for TACE procedures (see
next paragraph), and hence the results are not comparable.
Importantly, our multivariate model revealed that well-estab-
lished prognostic factors, including the presence of MVI and
the extent of liver disease,16,18–20 were independently associated
with a worse survival in our population, providing face validity
to our analysis, and hence, strengthening the value of the asso-
ciation between PES and OS. Third, when evaluating predictors
of survival after TACE, in addition to these well-established
variables, different investigators have reported a variety of pro-
cedure-related factors associated with a worse prognosis, such
as the selectivity of the approach, the type and number of
chemotherapeutic agents used, and the embolization tech-
nique.17,31 The findings from this study may explain these dif-
ferences by emphasizing a more biological relationship between
PES, as an inflammatory marker, with long-term outcomes.
Other studies have found inflammatory markers, such as a
high neutrophil to lymphocyte ratio, to be predictive of worse
survival,19,20 and our findings potentially validate this concept
using a clinical representation of such inflammatory response.
However, this biological association will need further study
and validation.
The association between PES and a worse survival has signif-
icant implications beyond its predictive ability to identify high-
risk patients. Our findings indicate that patients experiencing
PES derive minimal benefit from TACE, as the median and
3-year overall survival rate are only 16 months and 18%,
respectively. A novel approach to more aggressive treatment
strategies or multimodality therapies using systemic agents may
accomplish better responses and should be considered for these
patients.32,33 Similarly, when considering TACE, results from
our multivariate analysis support the use of sequential proce-
dures over isolated TACE, as this was found to be a protective
factor associated with improved survival. Other studies, includ-
ing a recent phase II/III trial, have found improved outcomes
with similar safety patterns for patients receiving TACE proce-
dures in a planned sequential fashion.34,35 An important find-
ing from our analysis relates to the ability to identify patients
at risk of PES. Interestingly, in addition to the burden of
Table 2 Multivariate Cox regression model examining the
association of selected variables with risk of death following TACE
(N = 144)
Predictors of Survival Hazard
Ratio
95 %
Confidence
Interval
P-value
ECOG 2–4 (versus 0–1) 2.5 0.7–8.8 0.144
ECOG Unknown 0.6 0.3–1.1 0.103
Multiple tumors (versus single
tumor)
0.9 0.5–1.5 0.575
Macrovascular invasion
(versus no macrovascular
invasion)
4.5 2.4–8.6 <0.001
Child B (versus Child A) 1.9 1.0–3.4 0.040
Child C (versus Child A) 6.3 2.7–14.5 <0.001
PES (versus no PES) 2.0 1.2–3.3 0.011
Multiple TACE (versus
single TACE)
0.4 0.3–0.8 0.004
PES, post-embolization syndrome (defined in Methods); TACE, transar-
terial chemoembolization.
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disease, we found that patients receiving DEB-TACE were less
likely to experience PES, when compared with those having
conventional TACE. Retrospective studies, prospective ran-
domized trials and a systematic review comparing DEB-TACE
with conventional TACE have found at least similar efficacy
and improved safety profile in patients treated with DEB-
TACE.36–39 Although none of these reports evaluated differ-
ences in PES, in this context, our findings would support the
use of DEB-TACE whenever possible. Finally, patients experi-
encing a poor survival after TACE, such as those with MVI,
are typically not considered good candidates for this therapy,
and current guidelines do not recommend it.6,14 Although
selected patients with poor prognostic factors may benefit from
TACE,40 in addition to the considerations previously discussed,
alternative and evolving liver-directed therapies such as
transarterial radioembolization should be considered for this
high-risk population, particularly given recent data showing
equivalent survival and a lower incidence of PES.41–43
Several important limitations should be considered when
interpreting our study findings. Given the retrospective nature
of our study, some of our findings may be subject to selection
bias. Additionally, there is potential for unmeasured con-
founders that we were unable to adjust for in our analyses.
Nonetheless, we did adjust for all statistically significant covari-
ates in the final multivariate analysis. Although our study pop-
ulation was relatively small, this did not seem to hinder our
ability to identify PES as a statistically significant factor associ-
ated with worse a overall survival, and this is one of the largest
cohort studies of its kind, analysing TACE and OS. Our study
cohort was restricted to the Veteran population that was pre-
dominantly male, thereby potentially limiting the overall gener-
alizability of our study findings, in particular as it relates to
female patients and those with other comorbidity profiles.
Lastly, the findings observed in this study may be limited to
the TACE practice patterns from our centre, including the
preferential use of DEB over conventional TACE (including
lipiodol infusion).
In conclusion, we found PES to be a common complication in
patients with advanced, unresectable HCC. In the setting of
other well-established prognostic factors, PES is an early predic-
tor of worse OS for this population of patients. The biological
basis of this association may be related to the inflammatory nat-
ure of PES, although this needs to be further studied and charac-
terized. DEB-TACE should be the preferred approach whenever
possible as it is associated with a decreased risk of PES. Further,
for patients at an increased risk of PES, more aggressive strate-
gies (e.g. combined therapies) and/or other evolving liver-di-
rected therapies such as transarterial radioembolization should
be considered. Moving forward, PES must be viewed as a criti-
cally relevant event for patients with HCC, and future studies
should focus on validating these results using standardized
definitions that facilitate multi-institutional comparisons.
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